Powder makarova

 

(57) Abstract:

The invention relates to medicine, namely to pharmacology, and can be used in surgery, infectious diseases and dermatology. The invention consists in that a powder having an antibacterial effect, contains a filler of talc and zinc oxide, and further comprises powders methyluracil and metronidazole in a certain ratio. The invention provides a reduction of treatment time by reducing the time required to restore the integrity of the skin.

The invention relates to medicine, namely to pharmacology, and can be used in surgery, infectious diseases and dermatology.

Famous baby powder, which consists of zinc oxide (5 parts), starch (5 parts) and talc (40 parts) and is intended for the prevention and treatment of diaper rash of the skin in children under 1 year (M. D. Mashkovsky. Medicinal product. 1977, T. 1, page 297) is similar. The disadvantage of this powder are very narrow range of applications, weak therapeutic effect on skin lesions.

Closest to the technical nature of the claimed substance is a powder containing a filler, to yousee remedy for skin diseases (M. D. Mashkovsky. Medicinal product. 1977, so 2, page 357) prototype.

The disadvantages of the known powders are limited scope (only in dermatology for the treatment of hyperhidrosis), the formation of the crust in place of skin defect and later under her restore the integrity of the skin, which contributes to and may cause underneath the development of suppurative processes, caused by anaerobic flora.

The invention has been expanding application areas, not only in the treatment of skin diseases, and infectious diseases (for example, when tissue necrosis with meningococcal infection), and most importantly - in surgical practice and reduction of terms of treatment of patients.

The technical result - the reduction of the time required to restore the integrity of the skin by epithelialization from the periphery to the center of the damaged surface skin tissue at a rate of 1 mm per day, and use treatment when applying the prototype does not cause a therapeutic effect.

This result is achieved through the creation of such a composition, which is the rapid restoration of the integrity of the destroyed skin by epithelialization is politely as talc and zinc oxide, according to the invention, additionally introduced powders methyluracil and metronidazole at the following ratio, wt.%:

Methyluracil - 15-20

Metronidazole - 60-65

Filler - Rest

New, previously unknown features of the claimed substance powder Makarova are:

additional content methyluracil in the amount of 15-20 wt.%;

additional content metronidazole in the number of 60-65 wt.%;

additional therapeutic effect is not only skin, but also surgical diseases.

The method developed on the basis of determining therapeutic effect of the claimed substances in 120 patients with furunculosis, patients with trophic ulcers of the lower legs, bedsores gluteal region, with necrosis of soft tissues in acute meningococcal sepsis, skin burns, with sluggish granulating wounds with long-term healing skin wound contaminated with radionuclides.

Methyluracil took at least 15% and not more than 20%. When decreasing content methyluracil less than 15% decreased the effect of healing of skin ulcers and burns. Excess content methyluracil more than 20% leads to a decrease of the effect of healing of purulent skin lesions, especially caused by anaerobic flora, to the Oia purulent skin lesions, but the content more than 65% significantly reduces the effect of treatment of skin ulcers and burns.

The powder was prepared as follows: to known the powder, which is taken in the amount of 20.0 g, successively added 15.0 g of powder methyluracil and 65.0 g of powder of metronidazole, which is stirred in a glass vessel until a homogeneous mass.

Example 1. Patient Alymova, N., 48 years old, with trophic ulcers of the left tibia was appointed powder consisting of methyluracil 40% and metronidazole 40% and the filler - rest. The powder was applied to the skin defect was closed with a sterile gauze cloth, which was stronger on the skin adhesive strips. Ligation was performed daily with the application portion of the new powder and measuring the diameter of ulcers. Epithelialization has not occurred. The size of the skin defect is not decreased.

Example 2. Patient Alymova, N., 48 years old, with trophic ulcers of the left tibia was appointed powder consisting of 10% methyluracil and 80% of metronidazole and filler - the rest. The powder was applied to the skin defect was closed with a sterile gauze cloth, which was stronger on the skin adhesive strips. Ligation was performed daily with the application of a new portion of preprimer 3. Patient Alymova, N., 48 years old, with trophic ulcers of the left tibia was appointed powder consisting of 15% methyluracil and 65% of metronidazole and filler - the rest. The powder was applied to the skin defect was closed with a sterile gauze cloth, which was stronger on the skin adhesive strips. Ligation was performed daily with the application portion of the new powder and measuring the diameter of ulcers. The effect was positive. The size of ulcers decreased from the periphery to the center with a speed of 1 mm per day. Thus, the skin defect trophic ulcers with a diameter of 15 mm closed after 7 days. Trophic ulcers smaller disappeared before.

Example 4. Patient Lebedev P. C., 45 years old, with necrosis of the skin and soft tissues of the gluteal region in acute meningococcal sepsis (meningococcemia) dimensions h mm was applied daily powder consisting of 17% methyluracil and 62% of metronidazole and the rest is filler. The powder was applied to the skin defect was closed with a sterile gauze cloth, which was stronger on the skin adhesive strips. Ligation was performed daily with the application portion of the new powder and measuring the size of the skin defect. The effect was positive. Dimensions necrotic the rez 24 days.

Example 5. Patient Bogolyubov Century. N. , 48 years old, with thermal burns, 2nd degree, bubbles and skin tissue defect with a diameter of 37 mm was applied daily powder consisting of 20% methyluracil and 60% of metronidazole and filler - the rest. The powder was applied to the skin defect was closed with a sterile gauze cloth, which was stronger on the skin adhesive strips. Ligation was performed daily with the application portion of the new powder and measuring the diameter of the burn surface. The size of the burn tissue defect was decreased from the periphery to the center with a speed of more than 1 mm per day. Thus, the skin defect caused by thermal burn 2 degree diameter 37 mm, closed 12 days.

Example 6. Patient Yegorov A. N., 52 years, with an infected oshineye leather right hand with a diameter of 23 mm was applied daily powder consisting of 15% methyluracil and 65% of metronidazole and filler - the rest. The powder was applied to the skin defect was closed with a conventional adhesive tape. Ligation was performed daily with the application portion of the new powder and measuring the diameter of the skin defect. The effect was positive. The diameter of sadnenia decreased from the periphery to the center with a speed of 1 mm per day. Nanotube will find application in the treatment of disorders of the skin integrity of any origin (purulent and radiation wounds, sadnenia skin, sores, ulcers, necrosis of the skin and soft tissues in acute meningococcal sepsis, burn surface sluggish generiruushaya wounds and wounds that do not saulawa primary intention).

Powder having an antibacterial effect, containing an active substance and a filler, characterized in that the active substance contains methyluracil and metronidazole at the following ratio, wt. %:

Methyluracil - 15 - 20

Metronidazole - 60 - 65

Filler - The Rest

 

Same patents:

The invention relates to medicine, in particular to methods for antitumor compositions on the basis of fluorouracil, intended for injection

The invention relates to medicine and can be used for the treatment and prevention of complications in patients with operating and random superficial wounds

The invention relates to medicine, in particular tuberculosis and concerns chemotherapeutically antibacterial drugs for treatment of tuberculosis
The invention relates to medicine, to a tool that can be used for violations of protein metabolism as a General stimulator of metabolism, namely pharmaceutical composition having an anabolic effect, comprising as active principle an effective amount of potassium orotata and special additive in the amount of 45 to 55% by weight of the active substance

The invention relates to medicine, specifically to medicines, exhibiting anti-allergic, anti-asthma and anti-inflammatory effect

The invention relates to medicine, in particular to experimental tuberculosis

The invention relates to a new derivative of 4-oxo-1,4-dihydropyrimidin, specifically: 2,6-diethyl-5-phenyl-1(5,6-dimethylbenzimidazolyl-1)-4-oxo-1,4-dihydropyrimidine (I) having immunosuppressive activity, which can find application in medicine

The invention relates to medicine, namely to the means for treating frostbite

The invention relates to the field of medicine and relates to means for the treatment of wounds, burns, ulcers, radiation skin lesions, pressure sores

The invention relates to the field of pharmacology, and relates to pharmaceutical preparations for the treatment of gastritis, reflux esophagitis, duodenitis, dyspepsia and ulcers
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of blepharoconjunctivitis and blepharitis caused by the mite D

The invention relates to an improved process for the preparation of compounds of formula III

< / BR>
where R1is hydrogen or heteroaromatic, R2is a group selected from CH2-O-aralkyl, CH2OCO-alkyl, CH2ОСОNН2CH2ОСОРh, CH2LLC-alkyl; R3- C3-alkyl; R4- dichlorophenyl, including interaction of the compounds of formula I

< / BR>
where R1, R2and R3such as defined above, with a compound of formula II: R4-S-Hal, where R4like is definitely above and Hal represents halogen, in the presence of a base

The invention relates to medicine, namely to pharmaceutical compositions containing ondansetron and metacin

The invention relates to alkyl substituted cyclic amines of the formula I, where X and Y are in position 5, 6 or 7, where (i) n = 1, X represents (CH2)mCONR4R5, (CH2)mNR4CONR5, (CH2)mNHSO2R3(where m = 0 or 1, except that when m = 0, then Y cannot be hydrogen and Y is hydrogen or or6; (ii) n = 0 or 1, then X and Y are in the 0-position relative to each other and together form a: a) -C(O)NR10C(O)-, b) -C(O)NR4(CH2)xNR10C(O)- (where x = 0 or 1); (C) -CH2NR10C(O)-; d) -(CH2)NR10C(O) -, (e) -CH2C(O)NR10, g) -N(R3)-C(O)-O-, j) -CH2N(R8)CH2-; (iii) n = 0, and Y represents OR9then X is (CH2)mCONR4R5, (CH2)mNHCOR3(where m = 0 or 1); R1and R2represent, independently, WITH1-C8-alkyl, R3is1-C8-alkyl, aryl; R4and R5represent, independently, H, C1-C8-alkyl, C1-C6-alkylaryl or aryl; R6is1-C8-alkyl, R8is1-C8-alkyl, SO2R4(provided that R4is not hydrogen); R10is H, C is phenyl, possibly replaced by stands, nitro, chlorine, fluorine, bromine, amino, CN, carboxamido, acetyl; or represents thiophenyl, isoxazolyl, imidazolyl

The invention relates to medicine, veterinary medicine and relates to injectable dosage form of metronidazole

The invention relates to the field of organic synthesis, namely the way - obtain 1-(2-chlorophenyl)diphenyl-1H-imidazole (clotrimazole), which is used as an antifungal drug
The invention relates to medicine, namely to the experimental part, and can be used to study the therapeutic effect of reducing the function of the thyroid gland drugs, pathophysiology and morphology of the gland hypofunction

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with mixing water for injections, conservation agent, metronidasol till complete dissolving at 50-60 C, adding a buffer (NaOH solution) pH 4.5-6.5 at pre-estimated quantity of water, then one should sterilize the obtained medicinal form due to membranous filtration followed by sterile packaging. As a conservation agent one should apply sodium chloride at the quantity of 1.5-2.0 against metronidasol weight, then metronidasol solution should be supplemented with a half-volume of sodium chloride solution, after complete dissolving the obtained solution should be supplemented with the rest quantity of sodium chloride solution. As for membranous filtration it should be carried out by applying a capsule out of polypropylene with hydrophilic membrane of 1.2 mcm. The method provides no crystallization of an active substance during prolonged period of time.

EFFECT: higher therapeutic efficiency.

1 ex, 1 tbl

Up!